Compare UP & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UP | RZLT |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | United States | United States |
| Employees | 1250 | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 294.4M | 326.4M |
| IPO Year | N/A | 2011 |
| Metric | UP | RZLT |
|---|---|---|
| Price | $6.52 | $3.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $9.67 |
| AVG Volume (30 Days) | ★ 1.6M | 1.4M |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $1.07 |
| 52 Week High | $8.16 | $11.46 |
| Indicator | UP | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 79.16 | 51.51 |
| Support Level | $0.84 | $2.91 |
| Resistance Level | $8.16 | $3.73 |
| Average True Range (ATR) | 0.57 | 0.22 |
| MACD | 0.50 | -0.02 |
| Stochastic Oscillator | 77.26 | 44.70 |
Wheels Up Experience Inc is a provider of on-demand private aviation. The company offers a private aviation solution with a large and diverse aircraft fleet, delivered through a mix of charter solutions and its membership program that utilizes its controlled aircraft fleet and a network of safety-vetted charter operators. Through its partnership firm, it provides members and customers with an offering across private and premium commercial travel. It generates the majority of its revenue from member and customer flights through its membership program and charter solutions, as well as from membership fees and other activities and services, including group charter flights, cargo flights, and special missions. Geographically, the company generates maximum revenue from the United States.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.